Alivus Life Sciences Intrinsic Value
ALIVUS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹974.60 | ₹779.68 - ₹1169.52 | +3.1% | EPS: ₹44.30, Sector P/E: 22x |
| Book Value Method | asset | ₹2253.60 | ₹2028.24 - ₹2478.96 | +138.5% | Book Value/Share: ₹1126.80, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1889.80 | ₹1700.82 - ₹2078.78 | +100.0% | Revenue/Share: ₹1024.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1889.80 | ₹1700.82 - ₹2078.78 | +100.0% | EBITDA: ₹803.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1207.07 | ₹965.66 - ₹1448.48 | +27.7% | CF Growth: 0.3%, Discount: 15% |
| PEG Ratio Method | growth | ₹283.47 | ₹255.12 - ₹311.82 | -70.0% | EPS Growth: 5.6%, Fair P/E: 4.5x |
| Growth Adjusted P/E | growth | ₹679.80 | ₹611.82 - ₹747.78 | -28.1% | Revenue Growth: 4.6%, Adj P/E: 15.3x |
| ROE Based Valuation | profitability | ₹1889.80 | ₹1700.82 - ₹2078.78 | +100.0% | ROE: 19.3%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1059.78 | ₹953.80 - ₹1165.76 | +12.2% | EPS: ₹44.30, BVPS: ₹1126.80 |
Want to compare with current market value? Check ALIVUS share price latest .
Valuation Comparison Chart
ALIVUS Intrinsic Value Analysis
What is the intrinsic value of ALIVUS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Alivus Life Sciences (ALIVUS) is ₹1207.07 (median value). With the current market price of ₹944.90, this represents a +27.7% variance from our estimated fair value.
The valuation range spans from ₹283.47 to ₹2253.60, indicating ₹283.47 - ₹2253.60.
Is ALIVUS undervalued or overvalued?
Based on our multi-method analysis, Alivus Life Sciences (ALIVUS) appears to be trading below calculated value by approximately 27.7%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 18.83 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 19.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 30.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.75x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Alivus Life Sciences
Additional stock information and data for ALIVUS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹392 Cr | ₹84 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹414 Cr | ₹356 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹306 Cr | ₹233 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹598 Cr | ₹537 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹388 Cr | ₹354 Cr | Positive Free Cash Flow | 8/10 |